John Belperio
University of California, Los Angeles · David Geffen School of Medicine at UCLA, USA
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name John Belperio as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:42 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07538336 · Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft DysfunctionUniversity of California, San Francisco · not yet recruiting · Lung Transplant · principal investigator
- N/ANCT02631720 · CLAD Phenotype Specific Risk Factors and MechanismsNational Institute of Allergy and Infectious Diseases (NIAID) · completed · Lung Transplant, Post Lung Transplantation · study chair
- Ph2NCT01890265 · Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)Kyntra Bio · completed · Idiopathic Pulmonary Fibrosis · principal investigator
- Ph3NCT00650091 · Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPFDuke University · completed · Pulmonary Fibrosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:42 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- The UCLA Pulmonary and Critical Care Medicine Scientist Training Program (PCCM-STP)T32HL072752 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 2025 to 2026 · $276,719 awarded in 2026Same name and institution; not confirmed by an ID
- Validation of an in vitro model of progressive fibrosis that mimics Idiopathic Pulmonary FibrosisU01HL153000 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 2021 to 2024 · $617,814 awarded in 2024Same name and institution; not confirmed by an ID
- Immune Mechanisms of AlloinjuryR01HL112990 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 2012 to 2016 · $447,952 awarded in 2016Same name and institution; not confirmed by an ID
- The Role of Chemokines During Lung Allograft DysfunctionR01HL080206 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 2005 to 2009 · $329,610 awarded in 2009Same name and institution; not confirmed by an ID
- UCLA IPF Clinical Research NetworkU10HL080411 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 2009 · $197,025 awarded in 2009Same name and institution; not confirmed by an ID
- CHEMOKINE BIOLOGY IN BRONCHIOLITIS OBLITERANS SYNDROMEK08HL004493 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 2001 to 2005 · $121,770 awarded in 2005Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Idiopathic Pulmonary Fibrosis Clinical Research NetworkU10HL080413 · NHLBI · DUKE UNIVERSITY · PI Kevin J Anstrom · fiscal years 2005 to 2013Named on NCT00650091
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:42 UTC. The ranking covers the 200 most relevant of 8 PubMed records, and a shared surname and initials can bring in a namesake. All 8 on PubMed
- 59 citationsRCR 2.1
- Brief report: effect of ambrisentan treatment on exercise-induced pulmonary hypertension in systemic sclerosis: a prospective single-center, open-label pilot study.Arthritis Rheum · 201254 citationsRCR 1.8
- Elevated serum levels of the CXCR3 chemokine ITAC are associated with the development of transplant coronary artery disease.Circulation · 200348 citationsRCR 1.0
- 45 citationsRCR 4.1
- The Role of TGF-β in the Association Between Primary Graft Dysfunction and Bronchiolitis Obliterans Syndrome.Am J Transplant · 201642 citationsRCR 1.7
- Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment.Ann Rheum Dis · 201640 citationsRCR 1.8
- Impact of Allograft Injury Time of Onset on the Development of Chronic Lung Allograft Dysfunction After Lung Transplantation.Am J Transplant · 201723 citationsRCR 1.1
- Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial.BMJ Open Respir Res · 20236 citationsRCR 0.4